Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China

ize innovative therapies for patients with cardiorenal diseases. Tenapanor is one such therapy, and its acceptance by China's Center for Drug Evaluation is a significant achievement for Ardelyx. With the NDA submission expected to be approved by the end of 2024, this marks a major milestone in bringing tenapanor to patients in China. Ardelyx CEO expresses gratitude towards collaboration partner ..